May 23, 2007|
Pharma: The buying spree continues...
Given the highly competitive nature of the global generics market, consolidation has been gaining significant momentum in the past couple of years in the global generics industry. While 2005 saw Teva and Sandoz make headlines for acquiring Ivax and Hexal respectively, 2006 was when Dr.Reddy's (Betapharm) and Ranbaxy (Terapia) made strides on the consolidation front. It is now 2007 and already three companies have joined the acquisition bandwagon namely Mylan (Merck Generics), Wockhardt (Negma Laboratories) and the most recent Sun Pharma (Taro Pharma).
The aim of these acquisitions has been pretty obvious. To acquire scale in the global generics market where the prices continue to erode relentlessly on the back of increasing competition. The aim is also to be present across geographies and mitigate the risks in one particular market by a strong performance in another market.
The one notable feature of these acquisitions has been the fact that companies including Ranbaxy and Dr.Reddy's have been focusing on strengthening their presence in the emerging markets (where the products are branded and consequently enjoy higher margins). While the US generics market continues to be a major focus area for most of the major Indian pharma companies, many of them are looking to de-risk their business model by increasing focus on the semi regulated markets of Asia, Russia, CIS, Central Eastern Europe and Africa. This is largely due to the fact that while the US generics market continues to be the largest in the world, increasing level of competition and brutal price erosion has led Indian pharma companies to focus on other markets to sustain their overall revenue and profitability growth.
While the acquisitions made by the Indian pharma companies are expected to augment the overall performance in the longer term, challenges are abound in the medium term. Some of aspects that need to be addressed are as follows:
Successful restructuring: Integrating and restructuring the acquired company is critical to derive value from the acquisition in the longer term. To put things in perspective, Sun Pharma acquired Taro Pharma, an Israeli company, on Monday for US$ 454 m, making it the second largest acquisition by an Indian pharma company after Dr.Reddy's. While the financials for 2006 have not been divulged yet, it must be noted that Taro has ended 2006 with considerable losses. While Sun Pharma's strategy has been to acquire loss-making companies and turn them around, it has been successful in the past. Nevertheless this being a much bigger acquisition - is likely to dent the margins of the company in the medium term. Also, while Taro is expected to add value to the company in the longer term, everything hinges on how soon Sun Pharma will be able to turn it around.
Overcoming regulatory risks: Given the fact that different countries have different regulatory environments, changes in regulatory policies could impact the performance of the acquired company and thus increase the payback period for the acquirer. For instance, the regulatory changes in the German market have put pressure on Betapharm, which was acquired by Dr.Reddy's last year. Betapharm has had to undertake price cuts on a host of its products, which have dented the margins of the company. Thus, the key challenge for Dr.Reddy's is to consistently launch new products in the market and boost volumes to lessen the impact of the price erosion. Similarly, regulatory changes in Brazil has resulted in Ranbaxy having to re-file applications for its generic products impacting sales from this region in CY06.
Achieving cost synergies: Since a low cost advantage has become the prime requisite for survival in the generics market, achieving cost synergies from the acquisition also assumes importance. For instance, after acquiring Terapia, Ranbaxy sold off its manufacturing plant at Ireland and has chalked out plans to shift the production to the low cost manufacturing sites of Terapia. In fact Ranbaxy intends to make Terapia as a hub to cater to the European region now that it has become the member of the EU. Even in the CRAMS space, Nicholas Piramal shifted some of the production from Avecia to its sites in India to achieve efficiency at the operating level.
To sum up...
The global pharma industry is getting highly competitive and global generic companies are scrambling to acquire scale to have that 'edge' over their peers in terms of bargaining power and pricing. However, number of generic companies up for sale has been relatively lesser, pushing up valuations as a result. At the end of the day, what matters is how the company is able to derive value from the acquisition and augment the overall performance despite the slew of challenges in the medium term.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 17, 2017
Mr Trump is in the White House and the gods are in their heavens; what's not to like?
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407